English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Multiple myeloma (MM) is a clonal B-cell malignancy charactered by the aberrantproliferation of malignant plasma cells in the bone marrow. MM is still an incurablemalignancy. In this regard, novel treatments are urgently required. MUC1 (mucin1), a type І transmembrane protein, is overexpressed and aberrantly glycosylatedin many carcinomas particularly in MM resulting in an antigenically distinct moleculeand may be a potential target for specific immunotherapy. In this study, we firstdesigned a unique DNA vaccine, termed MUC1-2-VNTR (various number tandem repeats)to investigate whether the vaccine could specifically suppress tumor growth ina murine multiple myloma model. Our results showed that the constructed DNA vaccinepcDNA3.1-VNTR elicited both humoral and cellular tumor-specific immune responsesin the MM mouse model leading to delay in tumor growth and prolonged survivalof the mice. Consequently, our study indicates that this DNA vaccine shows promiseto be used as a novel strategy for the treatment of MM.

A unique MUC1-2-VNTR DNA vaccine suppresses tumor growth and prolongs survival in a murine multiple myeloma model